Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.

Abstract

Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

DOI: 10.1016/j.ejpn.2011.08.002
050100201220132014201520162017
Citations per Year

79 Citations

Semantic Scholar estimates that this publication has 79 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{DAmico2012RituximabIA, title={Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.}, author={A. D'Amico and Michela Catteruccia and F De benedetti and Marina S. Vivarelli and Manuela Colucci and Simona Cascioli and Enrico Silvio Bertini}, journal={European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society}, year={2012}, volume={16 3}, pages={301-3} }